Big news! Boehringer Ingelheim has submitted an application to the FDA requesting accelerated approval for idarucizumab, the reversal agent for Pradaxa (dabigatran). See: Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® Additionally, they have submitted for marketing approval by Health Canada and the European Medicines Agency (EMA). See: Boehringer …
Read More
Get a special discount on the FDA-approved AfibAlert® heart monitor for detecting atrial fibrillation. Lohman Technologies is making this special discount available for the StopAfib.org patient community for a limited time only, so please act quickly. To learn more, see: Special Discount on AfibAlert® Standalone Heart Monitor for Detecting Atrial Fibrillation.
Read More
Here's more good news about the upcoming antidote for Eliquis - see: Positive Results for Factor Xa Inhibitor Antidote: ANNEXA-A
Read More
Are you in the San Francisco area, or can you get there? Please join us for the Kickoff Conference of the Health eHeart Alliance Patient-Powered Research Network on November 6–7. We will identify research needs of the afib patient community and potential ways to address those needs. To learn more about the alliance and the …
Read More
Today, at the European Society of Cardiology Congress in Barcelona, it was reported that even though 80% of atrial fibrillation patients who should be on anticoagulants (according to their CHA2DS2-VASc score) are on anticoagulants, death rates at one year are still high. Most of those deaths are due to cardiovascular causes. The risk factors predicting …
Read More
Amazon Smile is the same Amazon you know already. Same products. Same prices. Same service. Now, by starting your shopping at smile.amazon.com, you can designate us to receive 0.5% of the price of your eligible purchases. You can support us without spending a cent more! It’s very easy to designate us as your supported charity …
Read More
While attending several recent medical conferences, we learned about some interesting procedure clinical trials that may be of interest to the afib patient community. To learn more, check out the following studies: The nContact CONVERGE Trial Will Study the Convergent Procedure for Treatment of Persistent Atrial Fibrillation The reMARQable Trial Will Study the nMARQ Multielectrode …
Read More
The StopAfib community in the US can now purchase the AliveCor Heart Monitor with an exclusive discount of 50% off. The AliveCor Heart Monitor is an easy-to-use, powerful, and accurate ECG-recording device that fits in your pocket and enables you to record an ECG anywhere, anytime. The AliveCor Heart Monitor is the only FDA-cleared mobile …
Read More
The new 2014 AHA/ACC/HRS Atrial Fibrillation Guidelines were just released at the American College of Cardiology annual conference. In this video interview, Dr. Hugh Calkins discusses what afib patients should know about the new afib guidelines. To watch the video, see: Dr. Hugh Calkins Discusses the New AHA/ACC/HRS Atrial Fibrillation Guidelines — Video Interview
Read More
Mellanie True Hills, founder of StopAfib.org, and electrophysiologist Dr. Hetal Bhakta will keynote Desert Regional Medical Center’s free seminar and health fair on February 14, 2014. To learn more, see: “Affair of the Heart” event
Read More